JPH10513358A - ヒト膵臓細胞系：発達と用途 - Google Patents

ヒト膵臓細胞系：発達と用途

Info

Publication number
JPH10513358A
JPH10513358A JP8524289A JP52428996A JPH10513358A JP H10513358 A JPH10513358 A JP H10513358A JP 8524289 A JP8524289 A JP 8524289A JP 52428996 A JP52428996 A JP 52428996A JP H10513358 A JPH10513358 A JP H10513358A
Authority
JP
Japan
Prior art keywords
cells
cell
vector
oncogenes
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP8524289A
Other languages
English (en)
Japanese (ja)
Inventor
レビネ、フレッド
ワング、シィジアン
エム． ビーティー、ジリアン
ヘイエク、アルベルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THE REGENTS OF THE UNIVERSITY OF CARIFORNIA
Original Assignee
THE REGENTS OF THE UNIVERSITY OF CARIFORNIA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/509,121 external-priority patent/US5723333A/en
Application filed by THE REGENTS OF THE UNIVERSITY OF CARIFORNIA filed Critical THE REGENTS OF THE UNIVERSITY OF CARIFORNIA
Publication of JPH10513358A publication Critical patent/JPH10513358A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP8524289A 1995-02-10 1996-01-25 ヒト膵臓細胞系：発達と用途 Ceased JPH10513358A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38689795A 1995-02-10 1995-02-10
US08/386,897 1995-02-10
US08/509,121 1995-07-31
US08/509,121 US5723333A (en) 1995-02-10 1995-07-31 Human pancreatic cell lines: developments and uses
PCT/US1996/001055 WO1996024669A1 (fr) 1995-02-10 1996-01-25 Lignees de cellules pancreatiques humaines: developpements et utilisations

Publications (1)

Publication Number Publication Date
JPH10513358A true JPH10513358A (ja) 1998-12-22

Family

ID=23527528

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8524289A Ceased JPH10513358A (ja) 1995-02-10 1996-01-25 ヒト膵臓細胞系：発達と用途

Country Status (8)

Country Link
EP (1) EP0808364B1 (fr)
JP (1) JPH10513358A (fr)
AT (1) ATE311466T1 (fr)
AU (1) AU716854B2 (fr)
BR (1) BR9607081A (fr)
CA (1) CA2210685A1 (fr)
DE (1) DE69635513T2 (fr)
WO (1) WO1996024669A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011034073A1 (fr) * 2009-09-15 2011-03-24 国立大学法人東京大学 Nouveau procédé de production de cellules différenciées

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110743A (en) * 1995-02-10 2000-08-29 The Regents Of The University Of California Development and use of human pancreatic cell lines
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
EP1905304A3 (fr) * 1997-10-09 2008-08-13 Wellstat Biologics Corporation Traitement de tumeurs avec des virus
US6132708A (en) * 1997-10-10 2000-10-17 Oregon Health Sciences University Liver regeneration using pancreas cells
DE10039844A1 (de) * 1999-08-10 2001-04-19 Hepavec Ag Fuer Gentherapie Kombinationsvektoren für den Gentransfer, Verfahren zu ihrer Herstellung und ihre Verwendung
GB0005856D0 (en) * 2000-03-10 2000-05-03 Reneuron Ltd Genetic constructs
GB0125773D0 (en) * 2001-10-26 2001-12-19 Reneuron Ltd Constructs
EP3257943B1 (fr) * 2010-11-02 2019-09-11 Helmholtz-Zentrum für Infektionsforschung GmbH Procédés et vecteurs pour l'immortalisation de cellules

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003882A1 (fr) * 1987-10-09 1989-05-05 Immunex Corporation Vecteurs retroviraux de transformation de promoteurs multiples
NZ226750A (en) * 1987-10-29 1990-09-26 Amrad Corp Ltd Immortalisation of neural precursor cells by introducing a retrovirus vector containing a myc-oncogene
AU3102289A (en) * 1988-03-11 1989-09-14 Dana-Farber Cancer Institute, Inc. Regulation of expression in mammalian cells
GB8928884D0 (en) * 1989-12-21 1990-02-28 Feldmann Marc Transformed cell lines
AU7312891A (en) * 1990-02-12 1991-09-03 Board Of Regents, The University Of Texas System Satellite cell proliferation in adult skeletal muscle
EP0455424A3 (en) * 1990-05-02 1992-04-29 Merck & Co. Inc. Mammalian inducible promoter cascade system
IT1264516B1 (it) * 1993-05-31 1996-09-24 Biotop Sas Di Rita Cassarin Cellule dendritiche immortalizzate
US5587309A (en) * 1994-04-29 1996-12-24 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating proliferation and differentiation of human fetal pancreatic cells ex vivo

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011034073A1 (fr) * 2009-09-15 2011-03-24 国立大学法人東京大学 Nouveau procédé de production de cellules différenciées
JP2015130866A (ja) * 2009-09-15 2015-07-23 国立大学法人 東京大学 分化細胞の新規製造法
JP5791191B2 (ja) * 2009-09-15 2015-10-07 国立大学法人 東京大学 分化細胞の新規製造法
US9200254B2 (en) 2009-09-15 2015-12-01 The University Of Tokyo Method for producing differentiated cells
JP2015213520A (ja) * 2009-09-15 2015-12-03 国立大学法人 東京大学 分化細胞の新規製造法
US10087419B2 (en) 2009-09-15 2018-10-02 The University Of Tokyo Method for producing differentiated cells

Also Published As

Publication number Publication date
MX9706019A (es) 1997-11-29
WO1996024669A1 (fr) 1996-08-15
EP0808364A1 (fr) 1997-11-26
BR9607081A (pt) 1997-11-11
AU4769496A (en) 1996-08-27
AU716854B2 (en) 2000-03-09
EP0808364B1 (fr) 2005-11-30
EP0808364A4 (fr) 2001-03-07
DE69635513T2 (de) 2006-08-17
DE69635513D1 (de) 2006-01-05
CA2210685A1 (fr) 1996-08-15
ATE311466T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
US5723333A (en) Human pancreatic cell lines: developments and uses
JP6335869B2 (ja) 複製可能レトロウイルスベクターの産生細胞
US6110743A (en) Development and use of human pancreatic cell lines
EP2344648B1 (fr) Vecteurs recombinants
JPH08502901A (ja) 真核細胞における、治療を目的とした遺伝子の移入と発現のためのレトロウィルスベクター
JPH07501688A (ja) ヒト筋肉細胞の単離、増殖、分化及び遺伝子工学の方法及び細胞
JP2000504584A (ja) 細胞の遺伝子修飾のための調節可能なレトロウイルス系
JPH09501055A (ja) 初代リンパ球への効率的遺伝子転移
EP1928504B1 (fr) Therapie de gene dans le foie
JP4011604B2 (ja) 後天性疾患治療用の新規移植組織片および新規ベクター
JP2003514565A (ja) 非分裂細胞を不死化する能力をもつベクター及び前記ベクターで不死化された細胞
EP1778295A1 (fr) Therapie genique de tumeurs solides par vecteurs retroviraux pseudotypes a arenavirus-glycoproteine
US6048725A (en) Recombinant human immunodeficiency virus producing cell lines
JPH08504573A (ja) 過剰増殖性細胞の複製阻害方法
JPH10513358A (ja) ヒト膵臓細胞系：発達と用途
JPH11511979A (ja) ヒト乳癌細胞を含むヒト乳腺細胞を標的として、連結された異種性遺伝子を発現させるためのｗａｐまたはｍｍｔｖ制御配列の使用
WO2022019325A1 (fr) Agent thérapeutique pour l'épidermolyse bulleuse dystrophique
US20030202967A1 (en) Development and use of human pancreatic cell lines
CA2202066A1 (fr) Lignees immortalisees de cellules endotheliales cerebrales et leurs applications therapeutiques
MXPA97006019A (en) Human pancreatic cellular lines: developments and u
JP2006501829A (ja) Ｈｏｘで誘導される増殖を制限する遺伝子をブロックする幹細胞増殖因子およびその方法
AU2006281912B2 (en) Liver-directed gene therapy
Pan et al. A combined gene delivery by co-transduction of adenoviral and retroviral vectors for cancer gene therapy
JP2003501066A (ja) Ｓｉｖベースのパッケージング欠損ベクター
JPH10511951A (ja) 高力価組換えレトロウイルスの産生および投与

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060524

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080701

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20081125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090127